New radioactive treatment for recurrent brain tumors
Part of Cancer clinical trials.
This early-stage trial tests a new radioactive drug called [177Lu]Lu-XT771 injected directly into the brain cavity after glioblastoma surgery. It measures whether the drug is safe and helps slow tumor regrowth in patients whose cancer has come back after earlier treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with glioblastoma that has come back after previous treatment
- Your tumor must be positive for certain markers (CA IX or CA XII) confirmed by imaging or biopsy
- You are between 18 and 80 years old, in good overall health (ECOG score 0–1), and expected to live at least 3 months
- You can have a small surgical reservoir (Ommaya) placed in your brain to receive the study drug
- Your blood counts, liver, and kidney function must be adequate; no active infections or uncontrolled bleeding
- You have not received recent cancer treatment (at least 2–4 weeks before, depending on the type) and have recovered from any side effects
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a radioactive drug that targets a protein on tumor blood vessels to treat glioblastoma that has come back after standard treatment. It may help shrink tumors or slow their growth.
This trial tests a new targeted drug, TLX101-Tx, added to standard care for people with glioblastoma that has come back after initial treatment. It aims to see if the combination helps control the tumor better than standard care alone.
This trial tests an experimental oral drug called CT-179, which targets a protein involved in brain tumor growth. It may help people with glioblastoma, a type of brain cancer, when standard treatments have not worked or as part of initial treatment.
This trial tests a combination of MRI-guided laser surgery, a wearable device (Optune) that sends electric fields to the brain, and an immunotherapy drug (pembrolizumab/Keytruda) for people whose glioblastoma has come back. The goal is to see if this approach is safe and works better than standard treatments.
This trial tests a combination of low-dose radiation, an immunotherapy drug (sintilimab), and chemotherapy (temozolomide) for people with glioblastoma that has come back. The goal is to see if this approach can help control the tumor and improve survival.
This trial tests a new approach that combines a drug (SONALA-001 or 5-ALA) with focused ultrasound to treat glioblastoma that has come back or is growing despite standard treatments. The drug makes tumor cells sensitive to sound waves, and the ultrasound waves are directed at the tumor using MRI guidance. This may help damage cancer cells while sparing healthy brain tissue.
Hear when a new Recurrent Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.